Prof Andrea Sartore-Bianchi speaks to ecancer in an online interview for the virtual ASCO 2021 meeting about the CHRONOS trial.
The phase II CHRONOS trial investigated anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in metastatic colorectal cancer (mCC).
Prof Sartore-Bianchi reports that 30% of patients presented with RAS, BRAF and EGFR mutations and were therefore excluded from the study.
He details that the 27 remaining patients were therefore treated with panitumumab and a 30% response rate was observed.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.